Among them, venetoclax is a well-studied BH3 mimetic drug that selectively antagonizes the antiapoptotic protein BCL-2, and its treatment effect is particularly significant in hematological malignancies [2]. The gene discussed is BCL2; the disease is hematologic disorder.